Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS

Coya Therapeutics announced plans to initiate an open-label extension of the Phase 2/3 ALSTARS trial evaluating COYA 302 for amyotrophic lateral sclerosis (ALS). The announcement cites requests from ALSTARS investigators; the provided article text ends before further details.

Analysis

The OLE is a retention and follow-up mechanism, not evidence that COYA 302 works: open-label outcomes are vulnerable to selection, expectation, and attrition effects, and should not be treated as a substitute for the randomized ALSTARS readout. Investigator requests may help sustain engagement and yield longer-duration safety or exposure data, but do not establish efficacy or broad patient demand. Near term, the announcement may support sentiment in a small clinical-stage name; the more durable valuation driver remains controlled-trial quality and timing. Over the next 1–3 months, verify the OLE protocol, eligibility, enrollment status, and whether any results will be presented; also check cash runway and the pivotal trial’s event/readout timeline. Over 6–18 months, credible controlled evidence could improve COYA’s partnering leverage, while weak or delayed data would leave the OLE with limited ability to offset the core trial risk. The contrarian point: an extension can look like clinical validation in promotional framing, but investor requests are not efficacy data. No competitor or supply-chain read-through is justified from the disclosed information.

Key Decisions for Investors

• Do not treat the OLE announcement alone as a reason to add risk to COYA; await verifiable details and the randomized ALSTARS evidence.
• For existing exposure, monitor the next company update for OLE design and trial timing, and separately verify cash runway before underwriting a longer catalyst window.
• A speculative event-driven position is only defensible after confirming the upcoming controlled-trial catalyst and liquidity; without those details, prefer a watchlist alert over options or a directional trade.
• Falsification: a material delay to the controlled readout, unfavorable randomized efficacy or safety data, or financing needs that materially dilute shareholders would weaken the thesis; a robust controlled signal would challenge the cautious view.